HealthKey.AI Acquires CancerBot: What It Means for CancerBot Users

We’ve spent the last several years building something we believe is genuinely rare in oncology software: a trial matcher that reasons the way a clinician does. EXACT doesn’t keyword-search ClinicalTrials.gov. It evaluates structured eligibility criteria against a structured patient record — criterion by criterion, with explicit pass/fail/indeterminate verdicts and the reasoning behind each one. That approach produces results that matter: patients who qualify for trials they would otherwise never hear about, and researchers who can trust that the patients knocking on their door have actually been screened.

That work continues. And it just got a lot more powerful.

CancerBot is now part of HealthKey

HealthKey.AI builds open infrastructure for disease-specific patient communities. Its customers are foundations — organizations like the ones that serve multiple myeloma, follicular lymphoma, CLL, and mantle cell lymphoma patients — and its mission is to give those communities the technology they need to support members at every step of their health journey: understanding their diagnosis, tracking their care, finding their next treatment option.

Trial matching is one of the most important things a disease foundation can offer its patients. By joining the HealthKey ecosystem, CancerBot becomes accessible to every community HealthKey serves — which means our trial matching and goodness scoring reach patients across disease types we couldn’t have prioritized on our own timeline. If you’re a patient in a HealthKey-powered community, EXACT is now part of the platform around you.

What we gain from HealthKey’s PHRAME infrastructure

HealthKey has built PHRAME — open-source components for personal health records — as shared infrastructure across its foundation partnerships. For CancerBot, this isn’t just a business arrangement; it’s a meaningful technical upgrade.

Richer patient records at the starting line. EXACT’s matching quality has always been a function of data completeness. A matcher that knows a patient’s ANC, prior therapy lines, and TP53 status returns far better results than one working from a diagnosis code and an age. PHRAME’s PHR components are designed to help patients build and maintain complete records — which means EXACT gets to match against better data, more often.

Structured OMOP from day one. Our patient data model, CTOMOP, is built on OMOP CDM. HealthKey’s infrastructure is being re-architected around OMOP and FHIR — the same standards we’ve spent years refining for oncology trial matching. We contributed to that architecture work, and we share a common data layer. The result is less friction at every integration point.

Standard of care recommendations and analytics. HealthKey’s platform layers in standard-of-care guidance and longitudinal analytics alongside trial matching. For patients, that means trial options and standard treatment options presented together in one coherent view — not siloed in separate tools. For researchers and navigators, it means the analytics to understand which patient populations are trial-ready and which are missing the data to know.

What this means in practice

For patients: if you’re part of a disease community powered by HealthKey, CancerBot’s trial matching is coming to you. The same matching engine that finds trials a physician’s manual review would miss — the structured eligibility evaluation that caught what a doctor’s office couldn’t see in thirty lines of free-text criteria — is now part of a broader platform that helps you understand your disease, track your care, and act on your options.

For trial researchers and principal investigators: CancerBot’s patient base is growing across disease types, all sharing a common structured data model. Precision enrollment — patients who have actually been evaluated against your eligibility criteria, not just pattern-matched on a keyword — becomes available to more sites and more communities.

For disease foundations: your patients get a trial matcher that was built from the ground up for the complexity of real oncology eligibility, backed by infrastructure that improves as every partner in the HealthKey network improves.

We get to focus on what we do best

One of the honest constraints of building precision trial matching is that the infrastructure problem is enormous. Patient record ingestion, FHIR pipelines, PHR management, analytics, standard-of-care content — doing all of that well while also building the best possible matcher is an unrealistic ask for a focused team.

HealthKey solves that problem. Their open PHRAME components handle the platform. We focus on the matcher: on expanding our trial catalog, improving eligibility extraction accuracy, refining our Goodness scoring rubrics, and serving more disease communities with the depth of matching that oncology patients deserve.

The mission hasn’t changed. Patients should be able to find the right trial — and know exactly why they qualify. We’re just better positioned now to deliver that at scale.